MX2023004216A - Emulsion farmaceutica oftalmica sin conservantes y su aplicacion. - Google Patents
Emulsion farmaceutica oftalmica sin conservantes y su aplicacion.Info
- Publication number
- MX2023004216A MX2023004216A MX2023004216A MX2023004216A MX2023004216A MX 2023004216 A MX2023004216 A MX 2023004216A MX 2023004216 A MX2023004216 A MX 2023004216A MX 2023004216 A MX2023004216 A MX 2023004216A MX 2023004216 A MX2023004216 A MX 2023004216A
- Authority
- MX
- Mexico
- Prior art keywords
- retinal
- occlusion
- preservative
- application
- ophthalmic pharmaceutical
- Prior art date
Links
- 239000008251 pharmaceutical emulsion Substances 0.000 title abstract 2
- 201000007527 Retinal artery occlusion Diseases 0.000 abstract 6
- 208000004644 retinal vein occlusion Diseases 0.000 abstract 5
- 201000005845 branch retinal artery occlusion Diseases 0.000 abstract 2
- 201000005849 central retinal artery occlusion Diseases 0.000 abstract 2
- 201000005667 central retinal vein occlusion Diseases 0.000 abstract 2
- 210000003733 optic disk Anatomy 0.000 abstract 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical class CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 208000032253 retinal ischemia Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Medical Informatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona una emulsión farmacéutica oftálmica sin conservantes que contiene un derivado de prostaglandina F2a donante de óxido nítrico o sales o ésteres farmacéuticamente aceptables del mismo como principio activo. La presente invención también proporciona su aplicación para promover la velocidad sanguínea de la cabeza del nervio óptico (CNO) para tratar pacientes con glaucoma y reducir los riesgos de glaucoma de ángulo abierto y enfermedad de isquemia retiniana, tal como oclusión de la vena retiniana (OVR), incluidas oclusión de la vena central de la retina (OVCR) y oclusión de la vena retiniana de rama (ORVR) y oclusión de la arteria retinal (OAR), incluidas oclusión de la arteria central de la retina (OACR) y oclusión de la rama de la arteria retiniana (ORAR).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263330324P | 2022-04-13 | 2022-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004216A true MX2023004216A (es) | 2023-10-16 |
Family
ID=86006840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004216A MX2023004216A (es) | 2022-04-13 | 2023-04-11 | Emulsion farmaceutica oftalmica sin conservantes y su aplicacion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230330104A1 (es) |
| EP (1) | EP4260845A1 (es) |
| JP (1) | JP2023157012A (es) |
| KR (1) | KR20230147006A (es) |
| CN (1) | CN116898800A (es) |
| AU (1) | AU2023202162A1 (es) |
| CA (1) | CA3195291A1 (es) |
| IL (1) | IL302062A (es) |
| MX (1) | MX2023004216A (es) |
| TW (1) | TW202345853A (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2767136T3 (es) * | 2004-01-05 | 2020-06-16 | Nicox Sa | Derivados de prostaglandinas |
| EP2016936B1 (en) * | 2007-07-09 | 2010-09-15 | Novagali Pharma S.A. | Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
| KR20190104993A (ko) * | 2016-11-08 | 2019-09-11 | 보오슈 앤드 롬 인코포레이팃드 | 정상 안압 녹내장을 치료하기 위한 산화질소 방출 프로스타글란딘 유도체 |
| AU2018323861B2 (en) * | 2017-08-27 | 2023-08-17 | Rhodes Technologies | Pharmaceutical compositions for the treatment of ophthalmic conditions |
| CN109172580B (zh) * | 2018-09-06 | 2021-04-27 | 中山万汉制药有限公司 | 包含前列腺素衍生物的组合物以及包含该组合物的眼用液体制剂 |
| JP2022541874A (ja) * | 2019-06-11 | 2022-09-28 | サイファイ エス．ピー．エー． | マイクロエマルション組成物 |
-
2023
- 2023-04-06 CA CA3195291A patent/CA3195291A1/en active Pending
- 2023-04-07 AU AU2023202162A patent/AU2023202162A1/en active Pending
- 2023-04-11 MX MX2023004216A patent/MX2023004216A/es unknown
- 2023-04-11 TW TW112113470A patent/TW202345853A/zh unknown
- 2023-04-11 EP EP23167362.5A patent/EP4260845A1/en active Pending
- 2023-04-11 CN CN202310376113.0A patent/CN116898800A/zh active Pending
- 2023-04-12 US US18/133,984 patent/US20230330104A1/en active Pending
- 2023-04-12 KR KR1020230047919A patent/KR20230147006A/ko active Search and Examination
- 2023-04-12 JP JP2023064996A patent/JP2023157012A/ja active Pending
- 2023-04-13 IL IL302062A patent/IL302062A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116898800A (zh) | 2023-10-20 |
| KR20230147006A (ko) | 2023-10-20 |
| IL302062A (en) | 2023-11-01 |
| CA3195291A1 (en) | 2023-10-13 |
| TW202345853A (zh) | 2023-12-01 |
| AU2023202162A1 (en) | 2023-11-02 |
| US20230330104A1 (en) | 2023-10-19 |
| JP2023157012A (ja) | 2023-10-25 |
| EP4260845A1 (en) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020125355A (ja) | 併用療法 | |
| ES2348314T3 (es) | Derivados de mononitrato de isosorbida para el tratamiento de la hipertensión ocular. | |
| RU2013125146A (ru) | Комбинация фолиевой кислоты и рамиприла: цитопротекторные, нейропротекторные и ретинопротекторные офтальмологические композиции | |
| JP6944958B2 (ja) | 持続性浮腫を伴う滲出性加齢黄斑変性の処置のためのシロリムスの使用 | |
| JPWO2010010702A1 (ja) | 軸性近視の予防または治療剤 | |
| MX2023004216A (es) | Emulsion farmaceutica oftalmica sin conservantes y su aplicacion. | |
| KR20200123095A (ko) | 각막 보호용의 조성물 | |
| CN102762195B (zh) | 前列腺素激动剂前药的稳定水性组合物及其使用方法 | |
| US20210138032A1 (en) | Non-antibody vegf antagonists for the treatment of neovascular glaucoma | |
| US9636347B2 (en) | Sustained release formulations for the treatment of intraocular pressure or glaucoma | |
| Qamar et al. | Comparison of the efficacy between an intravitreal and a posterior subtenon injection of triamcinolone acetonide for the treatment of diffuse diabetic macular edema | |
| MXPA04010132A (es) | Metodo para tratar trastornos vasculares mediados por el factor de crecimiento endotelial vascular. | |
| TWI809021B (zh) | 含有ＦＰ促效藥及β阻斷藥的青光眼治療劑 | |
| US20110257186A1 (en) | Compositions and methods for treating visual disorders | |
| CA2977697C (en) | Isoprenyl flavonoid derivatives useful in the treatment of ocular disorders | |
| JPWO2006098292A1 (ja) | 眼疾患治療剤 | |
| CN111297858B (zh) | 一种parp-1抑制剂及其药物组合物在制备治疗眼部疾病的药物中的应用 | |
| EP3949960A1 (en) | Compounds (in particular salotenolide) in the treatment of axonal damage | |
| Lattanzio et al. | Macular hole and intravitreal injection of triamcinolone acetonide for macular edema due to central retinal vein occlusion | |
| RU2623870C1 (ru) | Способ комплексного лечения инфекционного острого оптического неврита | |
| Sharma et al. | Management of Coats’ disease with RazumabTM (world’s first biosimilar ranibizumab) and laser photocoagulation: a case report | |
| GRAUL | Marijuana and Glaucoma | |
| SU1386197A1 (ru) | Способ регул ции офтальмотонуса при полостных офтальмологических операци х | |
| Yoo et al. | Supraciliary microstenting with phacoemulsification in patients with open-angle glaucoma and cataracts | |
| RU2541834C1 (ru) | Способ лечения "влажной" формы возрастной макулярной дегенерации |